A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemiaKatherine E. Masih, Javed Khan, Rebecca Gardner et al.|Blood Advances|2023Cited by 18
Abstract 3581: Multi-omic analysis identifies mechanisms of resistance to CD19 CAR T-cell therapy in children with acute lymphoblastic leukemiaKatherine E. Masih, Javed Khan, Rebecca Gardner et al.|Cancer Research|2022Cited by 1
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategiesAlexandra Dreyzin, Nirali N. Shah, Serifat Adebola et al.|Cytotherapy|2025Cited by 1
Abstract A11: A comprehensive and integrative omic analysis of multiply relapsed refractory pediatric pre-B cell acute lymphoblastic leukemia predicts response to CD19 CAR T-cell therapyKatherine E. Masih, Javed Khan, Rebecca Gardner et al.|Cancer Research|2020Cited by 0
Abstract LB-141: Increased epigenetic plasticity and tumor heterogeneity predict resistance to CD19 CAR T cell therapy in pre-treatment pediatric acute lymphoblastic leukemiaKatherine E. Masih, Rimas J. Orentas, Abdalla Abdelmaksoud et al.|Cancer Research|2020Cited by 0